Matthew L Rizk - JoVE Visualize

Showing results (41-50 of 52) with videos related to

Pageof 6

Sort By:

Journal of Clinical Pharmacology|March 11, 2015

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageMatthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.

Antimicrobial Agents and Chemotherapy|September 13, 2021

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure InfectionsDan Li, Philip E Sabato, Benjamin Guiastrennec, et al.

Journal of the Pediatric Infectious Diseases Society|November 20, 2015

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.

Antimicrobial Agents and Chemotherapy|June 20, 2018

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy ParticipantsElizabeth G Rhee, Matthew L Rizk, Nicole Calder, et al.

British Journal of Clinical Pharmacology|December 20, 2019

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatinPratik Bhagunde, Francheska Colon-Gonzalez, Yang Liu, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014

Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.

AIDS Research and Human Retroviruses|September 18, 2024

A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naïve HIV-Infected ParticipantsDirk Schürmann, Andreas Hüser, Frieder Pfäfflin, et al.

Clinical and Translational Science|March 26, 2025

Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19Akshita Chawla, Ruthie Birger, Brian M Maas, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2020

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)Ivan Titov, Richard G Wunderink, Antoine Roquilly, et al.

Clinical Trials (London, England)|March 3, 2025

Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.

Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:

Pageof 6

Journal of Clinical Pharmacology|March 11, 2015

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageMatthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.

Antimicrobial Agents and Chemotherapy|September 13, 2021

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure InfectionsDan Li, Philip E Sabato, Benjamin Guiastrennec, et al.

Journal of the Pediatric Infectious Diseases Society|November 20, 2015

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.

Antimicrobial Agents and Chemotherapy|June 20, 2018

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy ParticipantsElizabeth G Rhee, Matthew L Rizk, Nicole Calder, et al.

British Journal of Clinical Pharmacology|December 20, 2019

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatinPratik Bhagunde, Francheska Colon-Gonzalez, Yang Liu, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014

Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.

AIDS Research and Human Retroviruses|September 18, 2024

A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naïve HIV-Infected ParticipantsDirk Schürmann, Andreas Hüser, Frieder Pfäfflin, et al.

Clinical and Translational Science|March 26, 2025

Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19Akshita Chawla, Ruthie Birger, Brian M Maas, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2020

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)Ivan Titov, Richard G Wunderink, Antoine Roquilly, et al.

Clinical Trials (London, England)|March 3, 2025

Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.

Pageof 6